ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...